TABLE 1.

Summary of co-occurring genetic mutation of ROS1.

Co-occurring genetic mutation of ROS1	Effect
ROS1-EGFR	ROS1 rearrangement may be one of the mechanisms of resistance to EGFR inhibitors; Combination of EGFR inhibitors with crizotinib may be effective
ROS1-ALK	Both mutations are sensitive to crizotinib, suggesting crizotinib as a potential treatment
ROS1-KRAS	Limited response to crizotinib; Variable treatment outcomes
ROS1-MET	Variable treatment outcomes; Combined use of highly selective MET inhibitors with crizotinib is necessary
ROS1-BRAF	Limited information on treatment outcomes; No published reports on combined treatment with ROS1 and BRAF inhibitors
ROS1-TP53	Associated with a shorter survival time